NCT01644890View on ClinicalTrials.gov

A Phase III Study of NK105 in Patients With Breast Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

436

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

July 31, 2016

Study Completion Date

January 31, 2017

Conditions
Breast Cancer Nos Metastatic Recurrent
Interventions
DRUG

NK105

IV, Weekly

DRUG

Paclitaxel

IV, Weekly

Trial Locations (1)

Unknown

Japan Sites, Tokyo, Etc.

Sponsors
All Listed Sponsors
lead

Nippon Kayaku Co., Ltd.

INDUSTRY

NCT01644890 - A Phase III Study of NK105 in Patients With Breast Cancer | Biotech Hunter | Biotech Hunter